Thomas O Daniel
CIK 1538894 · see remarks · last filed 2026-09-25
Thomas O Daniel is a corporate insider who has filed 60 SEC Form 4 insider transactions across 6 companies since 2012. The most recent filing, for GOSS, was dated Sep 25, 2026. Across all open-market trades the lifetime net is −$31.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $4.6K across reported positions. 36 SEC filings were submitted jointly with CELGENE CORP /DE/.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CELGZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3115 MERRYFIELD ROW, SUITE 120
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GOSS | Director | 476 | $9.68 | $4.6K | $0 | 10 | 2026-09-25 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 6,370 | $11.19 | $71.3K | $0 | 5 | 2022-06-30 |
| LRMR | Director | — | $2.24 | — | $0 | 2 | 2021-05-17 |
| Larimar Therapeutics, Inc. (ZFGN) Delisted | Director | 1,621 | — | — | $0 | 8 | 2019-06-27 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | — | — | — | $0 | 2 | 2018-03-07 |
| CELGENE CORP /DE/ (CELGZ) Delisted | see remarks | 68,965 | — | — | -$31.31M | 33 | 2015-12-18 |
Recent Filings
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-25 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2025-06-26 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2022-07-15 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2022-06-30 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-10 | GOSS | Grant (A) | — | $0 | EDGAR |
| 2021-06-03 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-17 | LRMR | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.